checkAd
    Startseite > Aktien > Vaxart > Nachrichten
    Vaxart Aktie
    0,8994
     
    USD
    -9,46 %
    -0,0940 USD
    Letzter Kurs 23.05.24 Nasdaq
    0,8870
     
    USD
    1.200 STK
    Geldkurs 23.05.24
    0,8926
     
    USD
    800 STK
    Briefkurs 23.05.24
    ISIN: US92243A2006 · WKN: A2JD8X · SYM: VXRT · USA

    Neueste Nachrichten

    Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    23.05.24 · globenewswire · Vaxart
    Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
    13.05.24 · globenewswire · Vaxart
    Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
    07.05.24 · globenewswire · Vaxart
    Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
    30.04.24 · globenewswire · Vaxart
    Fokus Aktien mit extremen Handelsvolumen am Donnerstag, den 28.03.2024
    28.03.24 · wO Chartvergleich · Energiekontor
    Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
    27.03.24 · globenewswire · Vaxart
    Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    20.03.24 · globenewswire · Vaxart
    Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
    14.03.24 · globenewswire · Vaxart
    Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
    07.03.24 · globenewswire · Vaxart
    Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
    06.03.24 · globenewswire · Vaxart
    Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
    05.02.24 · globenewswire · Vaxart
    Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
    19.01.24 · globenewswire · Vaxart